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ABSTRACT
Purpose: The purpose of this study was to elucidate the efficacy and safety of carbonate 
apatite (CO3Ap) granules in 2-stage sinus floor augmentation through the radiographic and 
histomorphometric assessment of bone biopsy specimens.
Methods: Two-stage sinus floor augmentation was performed on 13 patients with a total 
of 17 implants. Radiographic assessment using panoramic radiographs was performed 
immediately after augmentation and was also performed 2 additional times, at 7±2 months 
and 18±2 months post-augmentation, respectively. Bone biopsy specimens taken from 
planned implant placement sites underwent micro-computed tomography, after which 
histological sections were prepared.
Results: Postoperative healing of the sinus floor augmentation was uneventful in all cases. 
The mean preoperative residual bone height was 3.5±1.3 mm, and this was increased to 
13.3±1.7 mm by augmentation with the CO3Ap granules. The mean height of the augmented 
site had decreased to 10.7±1.9 mm by 7±2 months after augmentation; however, implants 
with lengths in the range of 6.5 to 11.5 mm could still be placed. The mean height of the 
augmented site had decreased to 9.6±1.4 mm by 18±2 months post-augmentation. No 
implant failure or complications were observed. Few inflammatory cells or foreign body giant 
cells were observed in the bone biopsy specimens. Although there were individual differences 
in the amount of new bone detected, new bone was observed to be in direct contact with the 
CO3Ap granules in all cases, without an intermediate layer of fibrous tissue. The amounts of 
bone and residual CO3Ap were 33.8%±15.1% and 15.3%±11.9%, respectively.
Conclusions: In this first demonstration, low-crystalline CO3Ap granules showed excellent 
biocompatibility, and bone biopsy showed them to be replaced with bone in humans. CO3Ap 
granules are a useful and safe bone substitute for two-stage sinus floor augmentation.
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INTRODUCTION
Hydroxyapatite (HAp; Ca10[PO4]6[OH]2) has long been used for the reconstruction 
of bony defects in orthopedic surgery and in the field of dentistry [1,2]. HAp shows 
excellent biocompatibility and osteoconductivity, but a limitation of its use in bony defect 
reconstruction is that the material remains stable in the bone as a foreign body. HAp is 
poorly resorbed in vivo, and it can become a source of infection [3-5]. Although bone apatite 
is generally thought to be composed of HAp, in fact, human bone is not stoichiometric HAp; 
instead, it is carbonate apatite (CO3Ap; Ca10−a[PO4]6−b[CO3]c[OH]2−d), which contains 6%–9% 
by weight of carbonate in its apatite crystal structure [6]. Since CO3Ap is more soluble in 
acidic solution than HAp, CO3Ap is easily resorbed by osteoclasts [7,8]. Doi et al. [9] used a 
sintering method to fabricate a CO3Ap block. This sintered CO3Ap block contained up to 6% 
by weight of carbonate in its apatitic structure. Ishikawa et al. succeeded in fabricating low-
crystalline CO3Ap without a sintering step by utilizing a dissolution-precipitation reaction 
involving precursors such as low-crystalline calcite [10]. In their study, since the CO3Ap 
block was fabricated in the aqueous solution, it contained larger amounts of carbonate in 
its apatitic structure than the block that was fabricated using a sintering method, and its 
crystallinity was also similar to that of bone. It was also shown that CO3Ap upregulated 
the osteoblastic differentiation of human bone marrow cells earlier than sintered HAp 
[11]. CO3Ap showed faster bone formation than Bio-Oss® (Geistlich‐Pharma, Wolhusen, 
Switzerland) in a rabbit femur [12]. Taking into account these results, it is evident that 
CO3Ap possesses higher osteoinductivity than sintered HAp or BioOss®, and CO3Ap may be a 
superior bone substitute material and scaffold for bone regeneration than those alternatives. 
This evidence encouraged us to use CO3Ap granules in the treatment of human bone defects. 
Kudoh et al. previously reported the safety and efficacy of CO3Ap granules in single-stage 
sinus floor augmentation for cases in which the residual alveolar bone height was between 
3.7 and 6.0 mm [13]. The limitation of their study was that only radiographic images were 
evaluated, and no histomorphometric evaluations were performed. Therefore, little was 
determined about the resorption behavior and tissue response of CO3Ap in the human body.
The purpose of this study is to clarify the safety and efficacy of CO3Ap granules in sinus floor 
augmentation for a severely atrophic maxilla with a residual alveolar bone height in the range 
of 1.0–5.0 mm, with delayed implant placement. This study is the first histological evaluation 
of low-crystalline CO3Ap granules using bone biopsy specimens in humans.
MATERIALS AND METHODS
Patient selection
A multicenter single-arm prospective study was conducted at 3 university dental hospitals: 
1) the Department of Oral Surgery, Tokushima University Hospital, 2) the Dental Implant 
Clinic, Dental Hospital, Tokyo Medical and Dental University, and 3) the Rehabilitative 
Dentistry and Implant Center, Kyushu University Hospital. Since no bone substitutes are 
approved in Japan for use at implant placement sites, other bone substitutes could not be 
used as a control. The clinical trial, including the recruitment of patients, was performed 
from January 16, 2015 to May 16, 2017.
The study population was composed of patients who had been treated with implant surgery 
using a 2-stage sinus floor augmentation procedure on the maxillary posterior of the 
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edentulous region. In the study, 13 patients (4 male and 9 female) between the ages of 37 and 
77 years (mean age, 61.0±11.7 years) were selected according to the inclusion and exclusion 
criteria shown in Table 1.
This trial was conducted in accordance with the Good Clinical Practice Guidelines and the 
Declaration of Helsinki, and the protocol was reviewed and approved by the Institutional 
Review Board (approval No. 1993) of each hospital involved in the study. All participants 
provided informed consent in writing, and the trial was registered as JPRN-UMIN000019281 
in the University Hospital Medical Information Network in Japan and with the International 
Clinical Trials Registry Platform Search Portal of the World Health Organization.
Graft material
In this clinical trial, CO3Ap granules (code no. GCAP-01) were provided by GC Corporation 
(Tokyo, Japan). The particle size of CO3Ap was in the range of 600–1,000 µm (short diameter).
The method used to fabricate low-crystalline CO3Ap consists of 2 processes. First, a precursor 
block is fabricated. For example, calcite block, which is used as a precursor, is fabricated by 
exposing calcium hydroxide compact to CO2 [14]. The calcite block thus prepared cannot be 
washed out even when the block is immersed in an aqueous solution. Next, the precursor 
block is then immersed in a phosphate salt solution. As CO3Ap is the most stable phase 
thermodynamically at neutral and alkaline pH, the calcite block is transformed into a low 
crystalline CO3Ap that maintains its macroscopic structure based on the dissolution–
precipitation reaction. This low crystalline CO3Ap was found to upregulate differentiation of 
osteoblasts, and it was resorbed by osteoclasts [5,9], because CO3Ap was closer in chemical 
composition to bone mineral.
Two-stage sinus floor augmentation technique and bone biopsy
Local anesthesia was administered, and a horizontal incision was made along the alveolar 
crest in the edentulous site. Then, vertical incisions were made to elevate the mucoperiosteal 
flap. After elevation of a full-thickness mucoperiosteal flap, a lateral bony window of the 
sinus was made by using a small diamond bur, a steel round bur, or a piezosurgical unit 
(Piezosurgery®, Mectron Medical Technology, Carasco, Italy). The sinus floor membrane 
was separated from the floor of the sinus and carefully elevated with a mucosal elevator. We 
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Table 1. Inclusion and exclusion criteria for patients
Inclusion criteria Exclusion criteria
1.  Maxillary partial edentulism involving the 
premolar/molar areas
2.  Residual alveolar bone height of less than 5 
mm from the original sinus floor to the crest 
of the alveolar bone
3.  Between 20 and 80 years of age
1. Presence or history of malignant tumors or irradiation
2. Uncontrolled diabetes mellitus
3.  History of bone metabolism disease, such as osteoporosis, 
or history of bisphosphonate medication
4.  Immunodeficiency, infectious disease, or connective tissue 
disease
5.  Taking steroid or immunosuppressant medication (excluding 
local administration)
6.  Severe kidney, liver, blood, bone metabolism, or circulatory 
system disorder
7.  Pregnancy, possibly pregnancy, breastfeeding, or 
considering pregnancy
8. Alcohol or drug abuse
9. Psychological or psychiatric problems
10. Artificial dialysis
11. Maxillary sinus pathologies
12. Oral infections or uncontrolled periodontal disease
13.  Participation in another clinical trial program within 3 
months prior to attempted study entry
checked carefully for any perforation of the membrane. After the sinus floor membrane was 
elevated, CO3Ap granules were packed into the elevated space. Finally, the mucoperiosteal 
flap was repositioned and sutured. The patients were given prophylactic antibiotics after 
augmentation, and they were brought back in 7–10 days later for clinical evaluation and 
removal of the sutures. Implant placement was planned for 8±2 months after augmentation. 
Prior to implant hole preparation, a bone biopsy specimen was taken from the same 
site using a trephine bur (2.1 mm in diameter). The implant was placed according to the 
standard protocol from the respective implant manufacturer. Implant installation torque was 
measured using a drilling device (GC Implant Motor IM-III, GC Corporation). Figure 1 shows 
the treatment protocol for this clinical study and the time schedule of the evaluations using 
panoramic radiographs.
Radiographic examinations
Computed tomography (CT) examinations were performed before and 7±2 months after 
sinus floor augmentation to evaluate the morphology and the height of the alveolar bone. 
Panoramic radiographs were taken, and the height of the augmented site containing the 
alveolar bone and CO3Ap granules was measured at the following points:
i) First measurement: preoperative (within 4 months prior to sinus floor augmentation); 
ii) Second measurement: immediately after augmentation; iii) Third measurement: 7±2 
months after augmentation (within 1 month prior to implant placement); and iv) Fourth 
measurement: 18±2 months after augmentation.
The alveolar bone crest line, original sinus floor line, and grafted sinus floor line were traced 
by superimposition of the panoramic images (Figure 2). Elevated bone height (EBH), which 
represents the distance from the alveolar bone crest line to the CO3Ap-grafted sinus floor 
line, was measured at the planned implant placement site. The panoramic images were saved 
as Digital Imaging and Communications in Medicine files, and digital radiographs were then 
analyzed using the Osiris medical imaging software program (Open-Source, OsiriX Medical 
Imaging Software, http://www.osirix-viewer.com).
Histological examinations
Biopsy specimens were fixed in 10% buffered formalin and dehydrated in a graded alcohol 
series. Specimens were then embedded in a methyl methacrylate resin. Next, undecalcified 
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Figure 1. Treatment protocol (upper section) and time schedule of evaluations using panoramic radiographs 
(lower section). Panoramic radiographs were taken i) pre-sinus floor augmentation, ii) immediately after 
augmentation, iii) 7±2 months after augmentation, and iv) 18±2 months after augmentation. 
CO3Ap: carbonate apatite.
sections were cut into 4-µm-thick sections using a microtome. The sections were stained with 
hematoxylin and eosin and Villanueva-Goldner stains using standard techniques. The area of 
new bone or residual CO3Ap granules was measured on the histological sections using Image 
J software (National Institutes of Health, Bethesda, MD, USA), and the ratio of the area of new 
bone or residual CO3Ap granules to total specimen area was also calculated for each specimen.
Micro-CT (TOSCANER-30000mhd micro-CT scanner, Toshiba, Tokyo, Japan) scans of the 
bone biopsy specimens were obtained and stored using 3D Creator software (VG Studio MAX, 
Volume Graphics, Heidelberg, Germany).
Statistical analysis
The data were classified according to the values obtained from the radiographs and treatment 
records, and the means and standard deviations were calculated. Statistical analysis was 
performed using the Wilcoxon signed-rank test using SPSS version 23.0 (IBM Corp., 
Armonk, NY, USA). Differences were considered statistically significant at P<0.01.
RESULTS
Table 2 summarizes the patients, implants (length, diameter, and installation torque), and 
amount of CO3Ap granules used. The amount of CO3Ap used in each case was between 
0.4–2.5 cm3 (1.3±0.6 cm3). No perforation of the sinus membranes occurred during the 
augmentation. In all cases, the postoperative healing of the augmentation was uneventful, 
with no abnormal bleeding, pain, or swelling due to the CO3Ap granules. At 8±2 months after 
augmentation, it was possible to place 17 implants with lengths of 6.5–11.5 mm. The implant 
installation torque ranged from 12.0 to 50.0 Ncm, and the mean value was 25.1±13.2 Ncm. All 
implants achieved osseointegration.
Table 3 and Figure 3 show the changes in the mean EBH. Preoperative residual bone height 
in the molar region of the maxilla ranged from 1.0 to 5.0 mm, and the mean height was 
3.5±1.3 mm. The mean EBH increased to 13.3±1.7 mm immediately after augmentation with 
https://doi.org/10.5051/jpis.2019.49.6.382




Alveolar bone crest line
Grafted sinus floor
Original sinus floor
Figure 2. Diagram of the measurement of EBH at the planned implant placement site. 
CO3Ap: carbonate apatite, EBH: elevated bone height.
the CO3Ap granules, then decreased to 10.7±1.9 mm and 9.6±1.4 mm at 7±2 months and 18±2 
months after augmentation, respectively. The mean EBH at 7±2 months after augmentation 
was 19.5% lower than that immediately after augmentation, and the difference was significant 
(P<0.01). The EBH at 18±2 months after sinus floor augmentation had decreased from that at 
7±2 months after augmentation, and this decrease was statistically significant (P<0.01).
Clinically, no abnormal bone resorption was observed for the sites augmented with CO3Ap 
granules, and a bone height that could support implants was maintained. No implant failures 
or complications were observed up to 18±2 months after augmentation. Furthermore, no 
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Table 2. Description of patients, implants (length, diameter, and installation torque), and the amount of CO3Ap granules used
Patient Implants CO3Ap
Case No. Age Sex Site Preoperative residual  
bone height (mm)








1 69 F 25 4.4 Brånemark® MK-IV TiUnitea) 10.0 4.0 15.0 0.8
2 60 F 25 4.1 Straumann SLA®b) 8.0 4.1 36.0 1.8
3 56 M 16 3.3 Straumann SLActive®b) 8.0 4.1 49.0 1.5
4 64 F 25 2.6 Brånemark® MK-III TiUnitea) 10.0 3.8 14.0 1.9
5 43 F 26 5.0 OsseoSpeed® TX4.5c) 9.0 4.5 22.0 0.7
6 71 F 16 5.0 Straumann SLActive®b) 8.0 4.1 14.0 1.2
17 3.8 Straumann SLActive®b) 10.0 4.1 15.0
7 37 F 15 3.6 Setio® Plusd) 8.0 3.8 37.0 0.4
8 64 M 26 5.0 Straumann SLA®b) 8.0 4.8 30.0 1.5
9 67 F 25 5.0 Nobel Active®a) 8.5 4.3 12.0 1.4
26 2.0 Nobel Active®a) 11.5 4.3 13.0
10 50 F 14 3.0 Genesio® Plusd) 10.0 3.8 No data 2.5
15 1.4 Genesio® Plusd) 10.0 3.8 No data
16 1.0 Genesio® Plusd) 8.0 3.8 No data
11 77 F 27 3.6 Genesio® Plusd) 8.0 4.4 20.0 1.0
12 71 M 26 4.0 Setio® Plusd) 10.0 4.4 50.0 1.4
13 64 M 26 2.0 Genesio® Plusd) 6.5 3.8 24.0 0.8
Mean±SD 61.0±11.7 3.5±1.3 8.9±1.3 4.1±0.3 25.1±13.2 1.3±0.6
CO3Ap: carbonate apatite, M: male, F: female, Site: expressed using two-digit system, SD: standard deviation.
a)Nobel Biocare AB, Göteborg, Sweden, b)Straumann AG, Basel, Switzerland, c)Dentsply Implants, Mölndal, Sweden, d)GC Corporation, Tokyo, Japan.
Table 3. Bone height at implant placement site
Patient Bone height (mm)
Case No. Site Pre-sinus floor augmentation Immediately after sinus  
floor augmentation
7±2 months after sinus floor 
augmentation (implant placement)
18±2 months after sinus  
floor augmentation
1 25 4.4 15.0 13.0 12.0
2 25 4.1 11.0 10.0 9.4
3 16 3.3 12.0 9.0 9.5
4 25 2.6 15.0 13.0 11.4
5 26 5.0 13.0 10.8 8.6
6 16 5.0 14.5 9.0 8.6
17 3.8 13.0 15.0 10.0
7 15 3.6 12.0 8.6 8.0
8 26 5.0 11.0 10.0 9.3
9 25 5.0 13.0 10.0 10.0
26 2.0 14.0 13.0 12.0
10 14 3.0 14.0 10.5 10.0
15 1.4 17.0 11.5 10.0
16 1.0 15.0 11.0 8.3
11 27 3.6 12.0 8.0 8.6
12 26 4.0 14.0 11.5 11.2
13 26 2.0 11.0 8.3 7.0
Mean±SD 3.5±1.3 13.3±1.7 10.7±1.9a) 9.6±1.4a)
SD: standard deviation.
a)Significant difference compared to the elevated bone height immediately after sinus floor augmentation (P<0.01).
postoperative infection, redness, or persistent pain, such as pain due to an allergic reaction, 
was observed at the augmented sites under consideration. Therefore, the overall survival rate 
of the implants was 100% at approximately 31 months after implant placement.
Figure 4 shows surgical views of the maxillary sinus floor augmentation and implant placement 
in case 10. In this case, the preoperative residual bone heights of the planned implant 
placement sites (#15, 16, and 17) were 3.0, 1.4, and 1.0 mm, respectively (Figure 5A and E). 
CO3Ap granules (Figure 4A) were filled into the elevated space immediately after augmentation 
(Figure 4B and C). The EBH increased to 14.0, 17.0, and 15.0 mm at sites #15, 16, and 17, 
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Figure 3. EBH at the implant placement site. Statistically significant differences were observed in comparison to 
the EBH measured immediately after the augmentation. 




Figure 4. Graft material and surgical views of maxillary sinus floor augmentation and implant placement (case 
10). (A) The CO3Ap granules used in this clinical trial. (B) Preparation of the recipient site of the elevated space. 
(C) The elevated space filled with CO3Ap granules. (D) Implant placement observed 8 months after augmentation. 
CO3Ap: carbonate apatite.
respectively. At implant placement, 8 months after augmentation, some CO3Ap granules were 
observed on the surface of the augmented site (Figure 4D). New bone had formed around the 
CO3Ap granules and was combined with them. Although the EBH had decreased from 14.0 to 
10.9 mm at site #15, from 17.0 to 11.5 mm at site #16, and from 15.0 to 10.3 mm at site #17 by 
7 months after augmentation, an implant with a length of 10.0 mm could be placed into sites 
#15 and #16, and an implant with a length of 8.0 mm could be placed into site #17 (Figure 4D). 
By 18 months after augmentation, the EBH had decreased to 10.0 mm at sites #15 and 16 and 
to 8.3 mm at site #17. From the panoramic radiographs (Figure 5B, C, and D), the boundary 
line between the residual bone and the CO3Ap granules could be detected immediately after 
augmentation (see arrowheads in Figure 5B); however, it gradually became obscure and could 
no longer be detected at 18 months post-augmentation (Figure 5D). Figure 5E and F show 
CT images of the CO3Ap-grafted site before and 7 months after augmentation, respectively. 
Residual CO3Ap granules were observed as high-density areas in contact with the new bone. 
Figure 5G shows a micro-CT image of a bone biopsy specimen at 7 months after augmentation. 
The residual CO3Ap granules were in direct contact with the new bone without the presence of 
intermediate soft tissue.
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Figure 5. Radiographic examinations (case 10). Panoramic radiographs taken (A) pre-augmentation, (B) immediately after augmentation, (C) 7 months after 
augmentation, and (D) 18 months after augmentation. Arrowheads indicate the boundary line between residual bone and CO3Ap granules (B, C). Black arrows 
indicate the grafted sinus floor line, which is elevated by augmentation with CO3Ap granules (B-D). CT images of preoperative residual bone height at site #16 (1.4 
mm) (E) and the elevated bone height at 7 months after augmentation of the same site (17.0 mm) (F). The bone height was maintained until implant placement. A 
micro-CT image of the bone biopsy sample taken 8 months after augmentation (G). Newly formed bone (white arrows) in direct contact with CO3Ap granules (*). 
CO3Ap: carbonate apatite, CT: computed tomography.
The images in Figure 6 show bone biopsy sections from case 8 at 7 months after augmentation. 
The amounts of new bone and residual CO3Ap were 43.8% and 13.2%, respectively (Figure 6A). 
Few inflammatory cells or foreign body giant cells were observed around the CO3Ap granules 
(Figure 6B). New bone and CO3Ap granules were in direct contact with each other without any 
intermediate fibrous tissue (Figure 6C), and the CO3Ap granules were in the process of being 
replaced by new bone (Figure 6D). In the indicated area of Figure 6D, osteoblasts were observed 
on the surface of the CO3Ap granules (Figure 6E). In the serial section, using Villanueva-
Goldner stain, it was observed that new bone (red) was gradually being replaced with mature 
bone (green) (Figure 6F).
Table 4 shows the amounts of new bone and residual CO3Ap in biopsy specimens subjected 
to histological evaluation. Bone formation was observed in all cases; the amount of new bone 
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Figure 6. A histological microphotograph of case 8 taken 7 months after augmentation. (A) A lower-magnification image of the relevant section of the biopsy 
specimen. The amounts of NB and residual CO3Ap (*) were 43.8% and 13.2%, respectively. (B) Few inflammatory cells or foreign body giant cells were observed 
around the CO3Ap granules (*). (C) New bone was observed to be in direct contact with the CO3Ap granules (*) with no intermediate fibrous tissue. (D) Black 
arrowheads indicate the area of replacement of CO3Ap granules (*) with new bone. (E) A higher-magnification image. Arrows indicate that osteoblasts were 
observed on the surface of new bone. Asterisk indicates residual CO3Ap. (F) The serial section of Figure 6E (visualized with Villanueva-Goldner stain). Mature 
bone was stained in green, and new bone was stained in red. New bone was gradually being replaced with mature bone (white arrowheads). 
NB: new bone, CO3Ap: carbonate apatite.
Table 4. The amount (%) of bone and residual CO3Ap obtained by histomorphometric evaluation in all cases















CO3Ap: carbonate apatite, SD: standard deviation.
ranged from 11.7% to 63.7%, and the amount of residual CO3Ap ranged from 0.0% to 35.3%, 
with individual variations among the cases. The mean amounts of new bone and CO3Ap were 
33.8%±15.1% and 15.3%±11.9%, respectively.
DISCUSSION
Bone biopsy examination revealed few inflammatory cells or foreign body giant cells, 
and new bone had formed around the residual CO3Ap granules in all cases. The CO3Ap 
granules were in direct contact with the new bone, with no intermediate fibrous tissue. 
The results obtained in this study clearly demonstrate the excellent biocompatibility and 
osteoconductivity of low-crystalline CO3Ap granules in humans, indicating that CO3Ap 
granules are a safe and useful bone substitute in two-stage sinus floor augmentation.
Implant insertion torque value, or installation torque value, has been a significant clinical 
indicator of primary implant stability and superior long-term implant survival rates [15,16]. 
Johansson et al. [17] reported that implant insertion torque values for failed implants 
were lower than the corresponding values for surviving stable implants. In our study, the 
installation torque values ranged from 12.0 to 50.0 Ncm (25.1±13.2 Ncm), and the values 
varied widely. No relationship was observed between the installation torque value and either 
the ratio of newly formed bone or the height of residual bone (data not shown). Dos Anjos et 
al. [18] performed implant placement 8 months after sinus floor augmentation with Bio-
Oss® and measured the installation torque. Their data indicated that all implants placed in 
the maxillary sinus presented higher installation torque values (35.0±9.8 Ncm) than those 
present in our results. However, installation torque value has been found to be affected 
by implant design and surgical technique. O'Sullivan et al. [19] measured the installation 
torque values of different implant designs in the maxillary bone of human cadavers, and the 
Brånemark Mark IV tapered implant showed a significantly higher installation torque than 
did the straight implants under study, including the Brånemark Standard implant, the Mark II 
implant, and the Osseotite implant. Tabassum et al. [20] demonstrated that implants placed 
with the undersized surgical technique showed higher installation torque values than those 
placed with the press-fit technique. Although the installation torque values from Dos Anjos's 
report were higher than those in our study, it is worth noting that they used tapered implants 
in all cases. In contrast, we used several kinds of implants, because multiple institutions 
were involved in the trial. Therefore, the variation in the installation torque values that we 
observed could very well be due to the variety of implant designs and surgical techniques 
used. In our study, all implants achieved osseointegration, and the overall survival rate at 
about 31 months after implant placement was 100%.
Figure 7 summarizes the reports of EBH reduction after 2-stage sinus floor augmentation 
using various bone substitutes. Deppe et al. [21] performed sinus floor augmentation solely 
with autogenous cortical bone obtained from the iliac crest or the mandible. The EBH 
reduction rates for the autogenous cortical bone graft at 11 months after augmentation 
were 21.5% in the iliac crest group and 15.9% in the mandibular bone group. Kim et al. 
[22] performed sinus floor augmentation with a mixture of Bio-Oss® and a small amount of 
autogenous cortical bone. EBH reduction from immediately after augmentation to 1 year after 
augmentation was 7.8%. In our study, EBH reduction at 18±2 months after augmentation was 
27.8%. Taking into account these results, we conclude that the order of resorption speed after 
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augmentation for the graft materials was, from fastest to slowest, autogenous cortical bone, 
then CO3Ap granules, and then Bio-Oss®.
Regarding the changes in EBH after implant placement, Deppe et al. [21] showed that 
EBH reduction for autogenous cortical bone grafts was 14.4% in the iliac crest group and 
8.4% in the mandible group at 5.5 months after implant placement, where the EBH at the 
time of implant placement was assumed to be 100%. Hieu et al. [23] performed sinus floor 
augmentation with Bio-Oss® alone. EBH reduction at 10 months after implant placement was 
6.5% compared to EBH reduction of 10.3% at 10±2 months after implant placement in our 
study. Therefore, the pace of EBH reduction after implant placement of CO3Ap granules was 
almost equal to that of autogenous cortical bone and faster than that of Bio-Oss®.
Figure 8 summarizes the reports on the rate of new bone formation in biopsy specimens from 
histological evaluation after sinus floor augmentation with autogenous bone and Bio-Oss®. 
Zerbo et al. [24] performed histomorphometric analysis and evaluated new bone formation 
after augmentation with autogenous cortical bone alone. The graft bone was harvested from 
the mandible, bone biopsy was performed at 6 months after augmentation, and the rate of 
new bone formation was 41.0%±10.0%. John and Wenz [25] performed histomorphometric 
analyses on bone biopsies harvested at 3 to 8 months after augmentation using mandibular 
bone alone. They reported that the bone formation rate for the mandibular bone was 
53.5%±2.5%. It has been proposed that the rate of new bone formation from autogenous 
cortical bone alone is approximately 40%–50%. New bone formation rates for Bio-Oss® 
were reported by John and Wenz [25], Sartori et al. [26], and Tadjoedin et al. [27] to be 
29.5%±7.4%, 29.8%±2.6%, and 22.9%±2.5%, respectively. Based on these reports, the rate 
of new bone formation with Bio-Oss® is approximately 20%–30%. In our study, the amount 
of new bone at 7±2 months after augmentation was 33.8%±15.1%. A comparison with other 
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Figure 7. EBH reduction rates in 2-stage sinus floor augmentation using various bone substitutes after sinus floor 
augmentation or implant placement. 
EBH: elevated bone height, CO3Ap: carbonate apatite. 
a)Deppe et al. [21]; b)Kim et al. [22]; and c)Hieu et al. [23].
graft materials, such as autogenous cortical bone and Bio-Oss®, was not performed in this 
study. However, Fujisawa et al. [12] demonstrated that a significantly larger amount of 
new bone formation was elicited in the cortical portion of a bone defect in a rabbit femur 
when reconstructed with CO3Ap granules than with Bio-Oss® at 8 weeks after implantation. 
Therefore, we surmise that the rate of new bone formation for CO3Ap granules is higher than 
that for Bio-Oss®.
John and Wenz [25] reported that the bone formation rate of a 2:1 mixture of Bio-Oss® 
and mandibular bone was 32.2%±6.9%. Tadjoedin et al. [27] demonstrated a relationship 
between the rate of new bone formation and the ratio of Bio-Oss® to autogenous cortical 
bone. The bone formation rates for 20%, 50%, 80%, and 100% Bio-Oss® were 37.3%±4.4%, 
33.6%±2.7%, 24.7%±2.4%, and 22.9%±2.5%, respectively. This revealed that the bone 
formation rate was inversely correlated with the amount of Bio-Oss®. These studies 
demonstrated that the rate of new bone formation for a combination of Bio-Oss® and 
autogenous cortical bone was approximately 24%–37%. In the same manner, adding 
autogenous cortical bone to CO3Ap granules would be expected to increase the rate of new 
bone formation compared to using CO3Ap granules alone.
Hallman et al. [28] and John and Wenz [25] performed sinus floor augmentation with Bio-
Oss® and reported the amounts of residual Bio-Oss® at implant placement to be 11.8%±3.6% 
and 14.9%±6.5%, respectively. In our study, the amount of residual CO3Ap granules at 7±2 
months after augmentation was 15.3%±11.9%, and the values varied widely. Fujisawa et 
al. [12] showed that the CO3Ap granules became smaller in size over time, and they also 
showed that the resorption speed for CO3Ap granules was faster than that for Bio-Oss® at 8 
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Figure 8. New bone formation rates in biopsy specimens from histological evaluation after sinus floor 
augmentation using autogenous bone, Bio-Oss®, CO3Ap granules. 
CO3Ap: carbonate apatite. 
a)Zerbo et al. [24], b)John and Wenz [25], c)Sartori et al. [26], and d)Tadjoedin et al. [27].
weeks after implantation, where implantation was made to a bony defect of a rabbit femur. 
Therefore, it is reasonable to expect that resorption of CO3Ap granules would also be faster 
than that of Bio-Oss® even in humans.
Galindo-Moreno et al. [29] and Moy et al. [30] reported the results of a histomorphometric 
study of bone biopsy specimens augmented with Bio-Oss® and HAp, respectively. 
Inflammatory cells and foreign body giant cells were rarely observed in the bone biopsy 
specimens of these materials. The new bone was in direct contact with the augmentation 
materials, without an intermediate layer of fibrous tissue. Bone biopsy of the CO3Ap granules 
showed similar findings (Figure 5), and these results indicate that CO3Ap granules possess 
excellent biocompatibility, like Bio-Oss® and HAp.
Although Bio-Oss® is widely used as a viable bone substitute, it is derived from a bovine 
source. Therefore, Bio-Oss® carries some risk of transmission of infectious diseases, such as 
bovine spongiform encephalopathy, via prions from cows to humans [31]. Moreover, there 
remains a possibility of the transmission of new infectious diseases stemming from unknown 
pathogens. Since Bio-Oss® is a natural material, there are also slight differences in stability 
and composition across product lots. In contrast, CO3Ap granules are a completely artificial 
synthetic bone substitute; therefore, they have never contained any pathogens, including 
prions, and they offer stable properties with no variation across product lots.
In conclusion, this study is the first in-human demonstration of the behavior of low-
crystalline CO3Ap granules from bone biopsy specimens. The results of this clinical study 
suggest that low-crystalline CO3Ap is a safe and beneficial bone substitute in two-stage 
sinus floor augmentation. Radiographic and histological examination of the bone biopsy 
specimens suggest that CO3Ap granules possess excellent biocompatibility without any risk 
of allergic reaction or immunological rejection, and they achieve adequate EBH for implant 
placement. In all cases, the postoperative recovery from augmentation with CO3Ap granules 
was uneventful. All implants achieved osseointegration and clinically showed no mobility 
at 31 months after implant placement. However, further study with a larger sample size and 
long-term follow-up with patients is needed for a more thorough evaluation.
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